银屑病关节炎诊断时CRP的意义及其与长期结局的关联
该真实世界研究分析609例银屑病关节炎(PsA)患者,按诊断时CRP水平分组(正常≤0.5 mg/dl vs 升高>0.5 mg/dl),比较临床特征与长期结局。多因素分析显示诊断时CRP升高独立关联BMI>25 kg/m2、附着点炎、高血压、新骨形成及「持续性疾病」。
要点
- 诊断时CRP升高的PsA患者中,附着点炎和新骨形成风险独立增加。
- CRP升高与心血管代谢负担(BMI>25、高血压)独立相关。
- CRP升高者「持续性疾病」风险显著增高(OR 4.36)。
核心结论
- 除新骨形成、附着点炎、「持续性疾病」及心血管代谢负担增加外,PsA总体特征与诊断时CRP水平无关。
研究设计与样本
- 真实世界研究,纳入609例PsA患者,按诊断时CRP>0.5 mg/dl(升高)或≤0.5 mg/dl(正常)分组。
- 比较人口学、临床特征、合并症及长期结局,并对单因素分析显著变量构建多因素logistic回归模型。
主要发现
- 609例中132例(21.7%)诊断时CRP正常,477例(78.3%)CRP升高。
- 单因素分析显示CRP升高与更长疾病随访时间、BMI>25 kg/m2、诊断时及病程中附着点炎、高血压、高尿酸血症、新骨形成及「持续性疾病」相关。
- 多因素分析显示诊断时CRP升高独立关联BMI>25 kg/m2(OR 1.69,95%CI 1.05-2.72)、附着点炎(OR 2.04,95%CI 1.24-3.38)、高血压(OR 2.07,95%CI 1.04-4.11)、新骨形成(OR 2.57,95%CI 1.33-4.94)及「持续性疾病」(OR 4.36,95%CI 2.22-8.59)。
关键数值与推荐
- CRP升高定义为>0.5 mg/dl,正常定义为≤0.5 mg/dl。
- 「持续性疾病」与诊断时CRP升高的OR为4.36(95%CI 2.22-8.59)。
- 新骨形成与诊断时CRP升高的OR为2.57(95%CI 1.33-4.94)。
临床怎么用
- 诊断时CRP升高的PsA患者应关注附着点炎、新骨形成及心血管代谢合并症(BMI>25、高血压)的评估与管理。
- CRP升高可能提示「持续性疾病」风险较高,需加强长期随访和疾病活动监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The role of CRP in PsA as a diagnostic and prognostic marker is debated. We compared clinical and epidemiological features, as well as long-term outcomes, between patients with 'elevated' (>0.5 mg/dl) and patients with 'normal' (≤0.5 mg/dl) CRP at diagnosis. METHODS: In this real-world study, we analysed data from 609 PsA patients categorized by their CRP at diagnosis. Demographics, clinical characteristics, comorbidities, and long-term outcomes were compared. The statistically significant variables in the univariate analyses were used to build two multivariable logistic regression models: (i) assessing associations between CRP and features at PsA diagnosis and (ii) examining its link with long-term outcomes (including 'difficult to manage' and 'persistent disease') and characteristics throughout the disease course. RESULTS: Of 609 patients, 132 (21.7%) displayed normal and 477 (78.3%) elevated CRP values at diagnosis. By univariate analysis, elevated CRP was associated with longer disease follow-up, BMI of >25 kg/m2, enthesitis (at diagnosis and during the disease course), hypertension, hyperuricaemia, new bone formation, and 'persistent disease'. By multivariable analyses, elevated CRP at diagnosis was independently linked with BMI of >25 kg/m2 [odds ratio (OR) 1.69, 95% CI 1.05-2.72], enthesitis (OR 2.04, 95% CI 1.24-3.38), hypertension (OR 2.07, 95% CI 1.04-4.11), new bone formation (OR 2.57, 95% CI 1.33-4.94) and 'persistent disease' (OR 4.36, 95% CI 2.22-8.59). CONCLUSION: Overall PsA characteristics are comparable, irrespective of the CRP levels at diagnosis, apart from new bone formation, enthesitis, 'persistent disease' and increased cardiometabolic burden, which were independently associated with elevated CRP levels at PsA diagnosis.
引用
- Dimopoulou AE, Papagoras C, Kyriazi N, et al. CRP at diagnosis in psoriatic arthritis: what it means and associations with long-term outcomes. Rheumatology (Oxford). 2026. PMID: 42565545. doi:10.1093/rheumatology/keag398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。